Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | HEXA | P06865 | 1/20 | 0.36 |
| ▸ | HEXB | P07686 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18015728 | 0.87 | EPHX2 (0.54) | EPHX2GRM4MLYCDHEXAHEXB | |
| SCHEMBL18590267 | 0.85 | GRM4 (0.40) | EPHX2GRM4MLYCDKIF11PPARG | |
| SCHEMBL24410388 | 0.78 | DRD2 (0.47) | HTR3AGRM4DRD2HTR2AHTR7 | |
| SCHEMBL12646428 | 0.78 | EPHX2 (0.56) | EPHX2HTR3AKIF11 | |
| SCHEMBL17233224 | 0.76 | MAPT (0.47) | HTR3AGRM4RAB9A | |
| SCHEMBL18302280 | 0.75 | EPHX2 (0.56) | EPHX2HTR3AKIF11 | |
| SCHEMBL17233427 | 0.75 | ESR1 (0.54) | — | |
| SCHEMBL20992201 | 0.74 | EPHX2 (0.52) | EPHX2HTR3AGRM4MLYCDKIF11 | |
| SCHEMBL18014810 | 0.72 | EPHX2 (0.55) | EPHX2GRM4KIF11 | |
| SCHEMBL8371409 | 0.70 | LMNA (0.58) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | CFD, F12, F3 | EPHX2 834/4885HTR3A 492/4885GRM4 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.